(NASDAQ: ZYME) Zymeworks's forecast annual revenue growth rate of 92.62% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.21%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Zymeworks's revenue in 2026 is $37,127,000.On average, 12 Wall Street analysts forecast ZYME's revenue for 2026 to be $21,530,452,904, with the lowest ZYME revenue forecast at $18,894,317,101, and the highest ZYME revenue forecast at $27,684,038,284. On average, 12 Wall Street analysts forecast ZYME's revenue for 2027 to be $21,297,706,594, with the lowest ZYME revenue forecast at $10,639,628,596, and the highest ZYME revenue forecast at $32,983,983,994.
In 2028, ZYME is forecast to generate $18,828,325,007 in revenue, with the lowest revenue forecast at $4,659,183,764 and the highest revenue forecast at $32,187,111,718.